ArticlePharmaceuticals (Basel, Switzerland)2023
Stabilization of Acne Vulgaris-Associated Microbial Dysbiosis with 2% Supramolecular Salicylic Acid.
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- 30% Supramolecular Salicylic Acid Improved Symptoms and Skin Barrier in Papulopustular Rosacea.Journal of cosmetic dermatology · 2025Trial
- Acne: epidemiology, risk factors, pathogenesis, management and cutting-edge research.Signal transduction and targeted therapy · 2026Review
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds.Health science reports · 2026Article
- From acidification to multi-targeted cellular modulation: dual impact of hydroxy acids on the skin microbiota and the epidermal barrier.Frontiers in cellular and infection microbiology · 2026Review
- Single-cell transcriptomics and spatial validation reveal dysfunction of keratinocytes and NK cells driving acne development.Scientific reports · 2025Article
- Analysis of Skin Microbiome in Facial and Back Acne Patients Based on High-Throughput Sequencing.Journal of cosmetic dermatology · 2025Article
- Skin microbiome influences the progression of cutaneous squamous cell carcinoma through the immune system.World journal of surgical oncology · 2025Review
- Effectiveness of Photodynamic Therapy, 2% Salicylic Acid, and Their Combination for Moderate Acne.Clinical, cosmetic and investigational dermatology · 2025Article
- Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies.International journal of molecular sciences · 2024Review
- Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances.Biochemistry and biophysics reports · 2023Review
- Role of the Microbiota in Skin Neoplasms: New Therapeutic Horizons.Microorganisms · 2023Review
- The updates and implications of cutaneous microbiota in acne.Cell & bioscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Facial microbiota dysbiosis is an important factor in causing acne vulgaris. The present study aimed to analyze the effect of 2% Supramolecular Salicylic Acid (SSA) on acne-associated facial bacteria. In the current study, 30 acne vulgaris patients (treated with 2% SSA for eight weeks) and ten volunteers with no facial acne were selected. Samples from acne patients (before and after treatment) and volunteers (not treated) were analyzed via high throughput sequencing, Deblur algorithm, and R microbiome package. After treatment with 2% SSA, the total lesion count and global acne grading system (GAGS) score reduced significantly (p < 0.001). Metagenomic sequencing analysis revealed that the pre-treated acne group had low α and deviated β diversity compared to the control and post-treated acne groups. Due to the treatment with 2% SSA, α diversity index was increased and β diversity was stabilized significantly (p < 0.001). The relative abundance of bacterial genera in the pre-treated acne group was uneven and had a high proportion of Staphylococcus, Ralstonia, and Streptococcus. The proportion of these three genera was significantly decreased in the post-treated group, and overall bacteria genera distribution tends toward the healthy individual. It is concluded that 2% SSA normalizes the microbial communities associated with the skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.